North American Morning Briefing: Banking Sector -3-
Bath & Body Works Cut to Hold From Buy by Argus Research
Braze Cut to Neutral From Buy by UBS
Bread Financial Cut to Market Perform From Outperform by Keefe, Bruyette & Woods
Cerevel Therapeutics Cut to Neutral From Overweight by JP Morgan
Columbia Banking System Raised to Overweight From Neutral by Piper Sandler
DigitalOcean Cut to Perform From Outperform by Oppenheimer
Dollar General Cut to Hold From Accumulate by Gordon Haskett
Duke Energy Raised to Neutral From Sell by Seaport Global
Emergent Biosolutions Cut to Underweight From Neutral by JP Morgan
Fidelity National Raised to Outperform From Market Perform by Keefe, Bruyette & Woods
First Republic Bank Cut to Neutral From Outperform by Wedbush
First Republic Bank Cut to Neutral From Overweight by Atlantic Equities
FMC Corporation Raised to Buy From Neutral by Redburn Partners
Honest Cut to Market Perform From Outperform by Telsey Advisory Group
Kaleyra Cut to Perform From Outperform by Oppenheimer
LivePerson Raised to Neutral From Underweight by Credit Suisse
Macrogenics Cut to Neutral From Buy by Guggenheim
Nvidia Raised to Overweight From Equal-Weight by Morgan Stanley
Ondas Holdings Cut to Perform From Outperform by Oppenheimer
QualTek Services Cut to Perform From Outperform by Oppenheimer
Qualtrics International Cut to Neutral From Outperform by Exane BNP Paribas
RingCentral Cut to Perform From Outperform by Oppenheimer
Sterling Bancorp Raised to Overweight From Neutral by Piper Sandler
Synchrony Financial Cut to Market Perform From Market Outperform by Keefe, Bruyette & Woods
Synchrony Financial Raised to Outperform From Perform by Oppenheimer
Terex Cut to Neutral From Buy by B of A Securities
Veeva Systems Cut to Hold From Buy by Truist Securities
Warner Bros. Discovery Raised to Outperform From Peer Perform by Wolfe Research
Warner Bros. Discovery Raised to Overweight From Equal-Weight by Wells Fargo
This article is a text version of a Wall Street Journal newsletter published earlier today.
(END) Dow Jones Newswires
March 20, 2023 05:55 ET (09:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
GE Aerospace Earnings: Fantastic Prospects for Stand-Alone Jet Engine Maker
-
Best Innovative Companies to Own: 2024 Edition
-
Truist Earnings: Expense Control Is Working and Near-Term Capital Flexibility Is Crucial to Growth
-
5 Growth Stocks to Buy From the Best Money Managers
-
Verizon Earnings: Price Increases Drive Solid Wireless Revenue Growth
-
2 Wide-Moat Stocks Trading at Rare Discounts
-
The Best Defensive Stocks to Buy
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?